Back | Next |
home / stock / cydy / cydy message board
Subject | By | Source | When |
---|---|---|---|
real shareholders deserved a CRO | theswordman | investorshub | 04/28/2023 5:19:26 PM |
I agree with a lot of what you | Since 2012 | investorshub | 04/28/2023 4:02:07 PM |
Hold lifted yet? | justdafactss | investorshub | 04/28/2023 3:17:21 PM |
It's all a step in the right direction. | Monroe1 | investorshub | 04/28/2023 2:51:44 PM |
I understand what you are saying about being | tmac20 | investorshub | 04/28/2023 10:57:50 AM |
We can all watch videos. Read about Italian | theswordman | investorshub | 04/28/2023 3:03:46 AM |
Yes , He said in the video | misiu143 | investorshub | 04/28/2023 2:39:59 AM |
And to think with the liver side effects | Monroe1 | investorshub | 04/28/2023 2:33:14 AM |
Can Blocking CCR5 Improve Brain Injury and Dementia | misiu143 | investorshub | 04/28/2023 12:35:05 AM |
$CYDY "no money"--that is hilarious | theswordman | investorshub | 04/27/2023 9:52:56 PM |
Monroe , haha , it took me a | misiu143 | investorshub | 04/27/2023 9:21:15 PM |
I don't know what , but changes should happen, | misiu143 | investorshub | 04/27/2023 8:24:39 PM |
Maybe we will see all these indications and | Monroe1 | investorshub | 04/27/2023 8:11:42 PM |
I have been reading that site every week | Monroe1 | investorshub | 04/27/2023 8:00:15 PM |
Thank you , interesting article , I don't | misiu143 | investorshub | 04/27/2023 7:52:46 PM |
Here's an older study of MS patients which | Fumbler | investorshub | 04/27/2023 6:26:52 PM |
Thank you! | 3X Charm | investorshub | 04/27/2023 5:36:05 PM |
Well in this case lets recall our HISTORICAL | theswordman | investorshub | 04/27/2023 4:44:56 PM |
https://www.cell.com/neuron/fulltext/S0896-6273(23)00268-4? returnURL=https%3A%2F%2Flinkinghub.elsev | misiu143 | investorshub | 04/27/2023 4:17:57 PM |
Wow thanks for that. CCR5 is involved in | jimmy667 | investorshub | 04/27/2023 1:58:20 PM |
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...
VANCOUVER, Washington, May 16, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, I write today to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), as we approach the end of our 2024 fiscal year (May 31, 2024), and to sincerely thank you for your unwavering...